+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Imiquimod 5% cream as an adjuvant pre-operative treatment for basal cell carcinoma of the periocular area



Imiquimod 5% cream as an adjuvant pre-operative treatment for basal cell carcinoma of the periocular area



Orbit 33(6): 471-473



Despite national guidelines in the UK, patients with low-grade periocular malignancies frequently wait a period of months for their surgery. We have devised a protocol of pre-treatment with an immune modulator in an attempt to reduce the tumour size whilst patients await surgery. We present a case series of 5 patients who used Imiquimod 5% cream (Aldara) for 4 weeks as an adjuvant treatment prior to the excision of periocular nodular basal cell carcinomas. We also assessed tolerability of the cream using a visual analogue scale and recorded adverse events. Our patients had an average 22% reduction in tumour area (range 3.31%-39.64%) whilst awaiting surgery. The medication had a good tolerability profile and there were no ocular adverse events. Due to the promising results, this pilot study demonstrates the feasibility and value of a planned multicentre, prospective research project to further explore these initial findings.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053693089

Download citation: RISBibTeXText

PMID: 25255050

DOI: 10.3109/01676830.2014.950296


Related references

Re: "Imiquimod 5% cream for the treatment of periocular basal cell carcinoma". Ophthalmic Plastic and Reconstructive Surgery 27(4): 305; Author Reply 305-6, 2011

Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma. Ophthalmic Plastic and Reconstructive Surgery 26(2): 100-102, 2010

Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial. Bmc Ophthalmology 15: 35, 2015

Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases. Journal of Drugs in Dermatology 5(5): 461-464, 2006

Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas. Journal of Ocular Pharmacology and Therapeutics 26(4): 373-379, 2010

Imiquimod 5% Cream as Pre-Treatment of Mohs Micrographic Surgery for Nodular Basal Cell Carcinoma in the Face, A Prospective Randomized Controlled Study Imiquimod As Pre-Treatment of Mohs. 2012

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream. Journal of Clinical and Aesthetic Dermatology 4(5): 39-43, 2011

Imiquimod 5% cream: a new treatment option for basal cell carcinoma. International Journal of Dermatology 41(Suppl. 1): 16-20, 2002

Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma. Skin Therapy Letter 10(6): 2-5, 2005

5% imiquimod cream for the treatment of large superficial basal cell carcinoma. Archives of Dermatology 140(10): 1286-1287, 2004

Successful treatment of basal cell carcinoma on the face with imiquimod 5% cream. ActaDermato-Venereologica82(6):477, 2002

Treatment of an extensive superficial basal cell carcinoma of the face with imiquimod 5% cream. International Journal of Tissue Reactions 27(3): 111-114, 2005

Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream. Australasian Journal of Dermatology 44(2): 123-125, 2003

The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome. Clinical and Experimental Dermatology 28(Suppl. 1): 19-23, 2003

Effect on basal cell carcinoma tumor defense mechanisms after treatment with imiquimod 5% cream. Journal of Investigative Dermatology 121(1): 0959, 2003